SCHEMBL24312275

SCHEMBL24312275

CC(C#Cc1cc(Cl)cc(N2CCOCC2)n1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ RAF1 P04049 7/20 0.36
▸ ATR Q13535 1/20 0.35
▸ PIK3CB P42338 3/20 0.34
▸ KIF18A Q8NI77 2/20 0.34
▸ NAPEPLD Q6IQ20 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312272 0.82 RAF1 (0.40) CYP1A2CYP3A4CYP2C9CYP2C19RAF1
SCHEMBL24312333 0.82 RAF1 (0.40) RAF1PIK3CBKIF18ANAPEPLDUSP2
SCHEMBL24312197 0.77 AKT1 (0.43) CYP1A2RAF1KIF18AUSP2TSHR
SCHEMBL24312255 0.76 AKT1 (0.39) CYP1A2RAF1ATRKIF18A
SCHEMBL24312208 0.74 KIF18A (0.40) CYP1A2RAF1PIK3CBKIF18A
SCHEMBL24312185 0.72 CYP1A2 (0.39) CYP1A2CYP3A4CYP2C9CYP2C19RAF1
SCHEMBL24312188 0.70 MAPT (0.39) CYP1A2PIK3CBKIF18ANAPEPLDUSP2
SCHEMBL24312182 0.70 KMT2A (0.46) CYP1A2CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL24312280 0.69 RAF1 (0.44) CYP1A2CYP3A4CYP2C9CYP2C19RAF1
SCHEMBL24595190 0.68 MAPT (0.47) CYP1A2CYP3A4CYP2C9CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-20220356160-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-11-10 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112170-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CYP1A2 4302/4885CYP3A4 4579/4885CYP2C9 4503/4885
US-11746095-B2 Inhibtors of RAF kinases RAF1, BRAF, ARAF CYP1A2 4124/4885CYP3A4 4563/4885CYP2C9 4713/4885
US-20220356160-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CYP1A2 4302/4885CYP3A4 4579/4885CYP2C9 4503/4885
US-11377431-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF CYP1A2 4302/4885CYP3A4 4579/4885CYP2C9 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback